US 11,919,940 B2
Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
Heiko Schuster, Tuebingen (DE); Janet Peper, Tuebingen (DE); Kevin Roehle, Tuebingen (DE); Philipp Wagner, Tuebingen (DE); and Hans-Georg Rammensee, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Sep. 2, 2021, as Appl. No. 17/465,381.
Application 17/465,381 is a continuation of application No. 17/372,136, filed on Jul. 9, 2021.
Application 17/372,136 is a continuation of application No. 17/117,191, filed on Dec. 10, 2020, abandoned.
Application 17/117,191 is a continuation of application No. 16/911,109, filed on Jun. 24, 2020, granted, now 10,899,820, issued on Jan. 26, 2021.
Application 16/911,109 is a continuation of application No. 15/881,078, filed on Jan. 26, 2018, granted, now 10,738,100, issued on Aug. 11, 2020.
Claims priority of provisional application 62/451,255, filed on Jan. 27, 2017.
Claims priority of application No. 10 2017 101 671.6 (DE), filed on Jan. 27, 2017.
Prior Publication US 2023/0002473 A1, Jan. 5, 2023
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12Q 1/6886 (2018.01); G16B 30/00 (2019.01)
CPC C07K 14/70539 (2013.01) [A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 16/2818 (2013.01); C07K 16/2833 (2013.01); C12Q 1/6886 (2013.01); G16B 30/00 (2019.02); A61K 39/00 (2013.01); A61K 2039/892 (2018.08); C07K 2317/34 (2013.01); C12Q 2600/156 (2013.01)] 20 Claims
 
1. A peptide consisting of the amino acid sequence FVDNQYWRY (SEQ ID NO: 115) in the form of a pharmaceutically acceptable salt.